Literature DB >> 28752489

Mechanism of New Bone Formation in Axial Spondyloarthritis.

Denis Poddubnyy1,2, Joachim Sieper3.   

Abstract

PURPOSE OF THE REVIEW: The purpose of this review is to discuss new evidence explaining the progress from bony inflammation over repair tissue to new bone formation in axial spondyloartrhitis and its correlations in imaging and histology of the bone. RECENT
FINDINGS: Data from imaging, histology and treatment interventions indicates that the disease starts with inflammation, followed by replacement of subchondral bone marrow by repair tissue which presence is crucial for the stimulation of new bone formation. The magnetic resonance imaging (MRI) sequences of STIR and T1 are currently the most commonly used imaging techniques to follow this process; explanations are offered for the limited sensitivity to detect these bony changes on MRI in their different phases. Early and effective anti-inflammatory treatment is crucial for the prevention of long-term ankylosis. Whether there are currently also treatment options targeting new bone formation in these patients directly is less clear.

Entities:  

Keywords:  Ankylosing spondylitis; Ankylosis; Axial spondyloarthritis; Bone formation; Radiographic progression; Structural damage

Mesh:

Substances:

Year:  2017        PMID: 28752489     DOI: 10.1007/s11926-017-0681-5

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  55 in total

1.  Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification.

Authors:  Walter P Maksymowych; Nathalie Morency; Barbara Conner-Spady; Robert G Lambert
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

2.  Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis--3-Year data of the ESTHER trial.

Authors:  In-Ho Song; Kay-Geert Hermann; Hildrun Haibel; Christian E Althoff; Denis Poddubnyy; Joachim Listing; Anja Weiß; Bruce Freundlich; Ekkehard Lange; Martin Rudwaleit; Joachim Sieper
Journal:  Semin Arthritis Rheum       Date:  2015-09-04       Impact factor: 5.532

3.  Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial.

Authors:  Denis Poddubnyy; Joachim Listing; Joachim Sieper
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

4.  Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis.

Authors:  Denis Poddubnyy; Hildrun Haibel; Joachim Listing; Elisabeth Märker-Hermann; Henning Zeidler; Jürgen Braun; Joachim Sieper; Martin Rudwaleit
Journal:  Arthritis Rheum       Date:  2012-05

5.  Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.

Authors:  X Baraliakos; F Heldmann; J Callhoff; J Listing; T Appelboom; J Brandt; F Van den Bosch; M Breban; Gr Burmester; M Dougados; P Emery; H Gaston; M Grunke; I E Van Der Horst-Bruinsma; R Landewé; M Leirisalo-Repo; J Sieper; K De Vlam; D Pappas; U Kiltz; D Van Der Heijde; J Braun
Journal:  Ann Rheum Dis       Date:  2013-07-14       Impact factor: 19.103

Review 6.  Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis.

Authors:  Barbara Neerinckx; Rik Lories
Journal:  Curr Opin Rheumatol       Date:  2017-07       Impact factor: 5.006

7.  Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis.

Authors:  Pedro Machado; Robert Landewé; Jürgen Braun; Kay-Geert A Hermann; Daniel Baker; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-24       Impact factor: 19.103

Review 8.  Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics.

Authors:  Heiner Appel; Joachim Sieper
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

9.  Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab.

Authors:  Jürgen Braun; Xenofon Baraliakos; Kay-Geert A Hermann; Stephen Xu; Benjamin Hsu
Journal:  J Rheumatol       Date:  2016-03-01       Impact factor: 4.666

10.  Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) - an open-label randomized controlled multicenter trial.

Authors:  Fabian Proft; Burkhard Muche; Joachim Listing; Valeria Rios-Rodriguez; Joachim Sieper; Denis Poddubnyy
Journal:  BMJ Open       Date:  2017-06-10       Impact factor: 2.692

View more
  21 in total

1.  Evaluation of serum fibroblast growth factor-23 in patients with axial spondyloarthritis and its association with sclerostin, inflammation, and spinal damage.

Authors:  Onay Gercik; Dilek Solmaz; Eyup Coban; Betul Ozbek Iptec; Gamze Avcioglu; Ozun Bayindir; Gokhan Kabadayi; Fatih Esad Topal; Didem Kozaci; Servet Akar
Journal:  Rheumatol Int       Date:  2019-04-09       Impact factor: 2.631

2.  [Advances in research on axial spondyloarthritis].

Authors:  J Rademacher; D Poddubnyy
Journal:  Z Rheumatol       Date:  2018-09       Impact factor: 1.372

Review 3.  [Pathogenesis of spondylarthritis : Relevance for treatment].

Authors:  J Sieper; D Poddubnyy
Journal:  Z Rheumatol       Date:  2020-02       Impact factor: 1.372

Review 4.  Current Unmet Needs in Spondyloarthritis.

Authors:  Denis Poddubnyy; Joachim Sieper
Journal:  Curr Rheumatol Rep       Date:  2019-07-13       Impact factor: 4.592

5.  HDAC1 regulates inflammation and osteogenic differentiation of ankylosing spondylitis fibroblasts through the Wnt-Smad signaling pathway.

Authors:  Yong Zeng; Rui He; Yong Liu; Ting Luo; Qing Li; Yu He; Miao Fang; Taiping Wang
Journal:  J Orthop Surg Res       Date:  2022-07-06       Impact factor: 2.677

Review 6.  The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.

Authors:  Joachim Sieper; Denis Poddubnyy; Pierre Miossec
Journal:  Nat Rev Rheumatol       Date:  2019-09-24       Impact factor: 20.543

7.  Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study.

Authors:  Xenofon Baraliakos; Sebastian Kruse; Simone E Auteri; Natasha de Peyrecave; Tommi Nurminen; Thomas Kumke; Bengt Hoepken; Jürgen Braun
Journal:  Rheumatology (Oxford)       Date:  2022-07-06       Impact factor: 7.046

8.  Low bone mineral density predicts the formation of new syndesmophytes in patients with axial spondyloarthritis.

Authors:  Hyoung Rae Kim; Yeon Sik Hong; Sung-Hwan Park; Ji Hyeon Ju; Kwi Young Kang
Journal:  Arthritis Res Ther       Date:  2018-10-16       Impact factor: 5.156

9.  ATF6 aggravates angiogenesis-osteogenesis coupling during ankylosing spondylitis by mediating FGF2 expression in chondrocytes.

Authors:  Mengjun Ma; Hongyu Li; Peng Wang; Wen Yang; Rujia Mi; Jiahao Zhuang; Yuhang Jiang; Yixuan Lu; Xin Shen; Yanfeng Wu; Huiyong Shen
Journal:  iScience       Date:  2021-06-28

10.  Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis.

Authors:  Berthold Hoppe; Christian Schwedler; Hildrun Haibel; Maryna Verba; Fabian Proft; Mikhail Protopopov; Hans-Gert Heuft; Valeria Rios Rodriguez; Anke Edelmann; Martin Rudwaleit; Joachim Sieper; Denis Poddubnyy
Journal:  RMD Open       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.